Actively Recruiting

Phase Not Applicable
Age: 19Years - 75Years
All Genders
ID04890171

Comparison of Endoscopic Submucosal Dissection and Surgery for Early Gastric Cancer With Undifferentiated Histological Type A Multicenter Randomized Controlled Trial

Led by National Cancer Center, Korea · Updated on 2024-12-27

708

Participants Needed

1

Research Sites

402 weeks

Total Duration

On this page

Sponsors

N

National Cancer Center, Korea

Lead Sponsor

S

Seoul St. Mary's Hospital, The Catholic University

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research aims to compare the clinical effectiveness and cost-effectiveness of endoscopic submucosal dissection (ESD) versus surgery for patients with early gastric cancer (EGC) of the undifferentiated type who meet specific expanded criteria. The study focuses on patients whose tumors are confined to the stomach lining without ulcers, are 2 cm or smaller, and show no signs of lymph node or distant metastasis. Previous studies suggested that ESD might offer better quality of life and lower medical costs than surgery, though surgery showed better disease-free survival in retrospective analyses. This trial seeks to provide stronger evidence through a multi-center, randomized controlled design.

CONDITIONS

Official Title

Comparison of Endoscopic Resection and Surgery for Early Gastric Cancer With Undifferentiated Histological Type

Who Can Participate

Age: 19Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with undifferentiated type early gastric cancer (signet ring cell carcinoma, poorly differentiated tubular adenocarcinoma, or poorly cohesive carcinoma) that meets expanded ESD criteria: tumor confined to the mucosa without ulcer and size 2 cm or less on endoscopy
  • No evidence of lymph node or distant metastasis on abdominal CT scan
  • Adults aged 19 to 75 years
  • Willingness to sign an informed consent form
Not Eligible

You will not qualify if you...

  • Under 19 years or over 75 years of age
  • Diagnosed and treated for other organ cancers (except carcinoma in situ and non-melanomatous skin cancer) within the past 5 years
  • Previous gastrectomy or esophagectomy
  • Multiple gastric cancers
  • Current treatment for serious medical conditions that may interfere with study participation, including severe heart dysfunction, liver cirrhosis, renal failure, chronic obstructive pulmonary disease or asthma, or uncontrolled infection
  • Unable to provide informed consent
  • Considered unsuitable for study enrollment by study physicians

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

National Cancer Center, Korea

Goyang-si, Gyeonggi-do, South Korea, 410-769

Actively Recruiting

Loading map...

Research Team

I

Il Ju Choi, MD, PhD

Y

Young-Il Kim, MD, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Development of an Artificial Intelligence System for Tumor R...

Artificial Intelligence

Actively Recruiting

1 location

Avutometinib and Defactinib Combination Treatment in Metasta...

Gastric Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here